Novo Nordisk, Eli Lilly & Co. and Sanofi dominate the market for insulin products worldwide, while the much-smaller Biocon is a key player in the copycat segment. The global insulin-pen market is ...

Analog insulin will still be available in the pen format under Novo's plan. Back in June, The New York Times reported that South Africa’s public health system had run out of human insulin pens ...

Novo Nordisk said Tuesday it will slash the list prices of several of its popular pre-filled insulin pens and vials by up to 75%, becoming the latest drugmaker to reduce the cost of the critical ...

Doctors Without Borders (MSF) is calling on Eli Lilly, Novo Nordisk and Sanofi to immediately reduce the price of insulin pens to $1 per device in low- and middle-income countries (LMICs).

LONDON, Nov 14 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab ... income countries will not suffer from the halting of insulin pen production, because the company is continuing to make ...

Novo Nordisk, a Danish drugmaker, announced it will cut some insulin prices in the United States up to 75% next year, amid pressure from competitors and lawmakers. The drugmaker will lower ...

followed by discontinuation of the Levemir injection pen in April and of Levemir vials by the end of 2024. Sign up here. Novo has another long-acting insulin, Tresiba, on the market. "Novo Nordisk ...

Pharmaceutical giant Novo Nordisk will lower the cost of several of its insulin products by up to 75% next year. Effective January 2024, the list price for insulin brands, including NovoLog and ...

Novo Nordisk A/S has entered into exclusive negotiations for a controlling stake in Biocorp SA, suppliers of Mallya, a Bluetooth-enabled smart add-on device for insulin pen injectors. The takeover ...

Novo launched the NovoPen - the first insulin pen device in 1985. Lars Rebien Sorensen becomes CEO after serving as the head of Novo's healthcare business. The company's enzymes business was spun ...